Download PDF

1. Company Snapshot

1.a. Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system.The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade.


The company was formerly known as Bolt Therapeutics, Inc.and changed its name to Bolt Biotherapeutics, Inc.in July 2015.


Bolt Biotherapeutics, Inc.was incorporated in 2015 and is headquartered in Redwood city, California.

Show Full description

1.b. Last Insights on BOLT

Bolt Biotherapeutics' recent performance was driven by its Q3 earnings report, which showed a narrower-than-expected loss and revenue beat. The company's cash balance of $38.8 million is anticipated to fund key milestones into 2027. Additionally, initial clinical data for BDC-4182 Phase 1 dose escalation study is expected in Q3 2026. The company's decision to modify the clinical trial protocol for BDC-4182 to allow for step-up dosing also boosted investor sentiment. Its upcoming earnings report is expected to beat estimates.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Nov -12

Source: zacks.com

Card image cap

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov -12

Source: globenewswire.com

Card image cap

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Nov -04

Source: zacks.com

Card image cap

CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)

Oct -20

Source: newsfilecorp.com

Card image cap

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Oct -01

Source: globenewswire.com

Card image cap

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Aug -14

Source: zacks.com

Card image cap

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug -14

Source: globenewswire.com

Card image cap

Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

Jun -11

Source: https://www.defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Novel Immunotherapies

Expected Growth: 11.3%

Bolt Biotherapeutics' novel immunotherapies drive 11.3% growth, fueled by increasing adoption in cancer treatment, advancements in gene editing technologies, and rising demand for personalized medicine. Additionally, strategic partnerships, expanding pipeline, and growing investments in R&D contribute to the company's rapid expansion.

7. Detailed Products

Boltezomab

A humanized monoclonal antibody that targets the tumor microenvironment to enhance anti-tumor activity

PBL-0393X

A bispecific antibody that targets both PD-1 and TGF-β to enhance anti-tumor activity

BDC-1001

A Boltbody™ immunotherapy that targets the tumor microenvironment to enhance anti-tumor activity

Boltbody™ Platform

A proprietary platform technology that enables the development of novel immunotherapies

8. Bolt Biotherapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bolt Biotherapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Bolt Biotherapeutics, Inc.'s products and services, which limits the ability of customers to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers in the market, but Bolt Biotherapeutics, Inc.'s dependence on a few critical suppliers increases their bargaining power.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for biotechnology products and services, and the relatively low barriers to entry in the industry.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the biotechnology industry, leading to a competitive market with high marketing and R&D expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 15.21%
Debt Cost 3.95%
Equity Weight 84.79%
Equity Cost 9.18%
WACC 8.39%
Leverage 17.93%

11. Quality Control: Bolt Biotherapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Arcutis Bio

A-Score: 5.0/10

Value: 6.2

Growth: 7.0

Quality: 5.5

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Bolt Biotherapeutics

A-Score: 3.7/10

Value: 9.6

Growth: 6.9

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Eterna Therapeutics

A-Score: 3.3/10

Value: 7.2

Growth: 5.0

Quality: 5.8

Yield: 0.0

Momentum: 1.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Arcus Biosciences

A-Score: 3.2/10

Value: 6.6

Growth: 3.6

Quality: 4.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Generation Bio

A-Score: 3.2/10

Value: 8.6

Growth: 5.4

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Lexicon Pharmaceuticals

A-Score: 2.8/10

Value: 6.6

Growth: 3.2

Quality: 4.4

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.31$

Current Price

5.31$

Potential

-0.00%

Expected Cash-Flows